ChongKunDang has introduced a news corporate identity in some 50 years since its establishment.
The new CI conveys the company’s goal to make a leap forward as a global pharmaceutical company.
ChongKunDang unveiled a newly changed CI and declared a future vision at a ceremony to celebrate the 84th anniversary at its headquarters in Chungjeong-ro, Seoul, on May 7.
The new CI stresses its image for global orientation by changing the symbol, font and color. The English CI abbreviates its English name from “ChongKunDang” to “CKD.”
The symbol enlarges the size of the bell to highlight ChongKunDang’s symbol.
The enlarging of the circle surrounding the bell and the expanding of the font of the slogan in the border of the circle emphasize the company’s mission for the health of human beings.
The use of the bell as its symbol dated back to a design contest in 1960.
At that time, a contest winner was evaluated to have transformed a sound into a visual image by converging the Korean character for “bell” with a cross-section of a bell, inspired by the sound of church bells at dawn, expressed in simple lines.
The font has employed “ChongKunDang Miraechae,” developed by the company. ChongKunDang Miraechae, a font harmonized by Dotum" and "Gulim" styles, gives a soft and powerful feeling.
The initial consonant “ㅈ” embodies a shape in which executives and staffers are united to make a leap forward for the future.
In particular, the removal of the quadrangle frame used in the former font and the enlarging of the size of the letters raises readability.
The new CI retains blue, ChongKunDang’s signature color, meaning birth, life and hope but raises its brightness to ramp up its image of bright future and eco-friendliness.
ChongKunDang Chmn. Lee Jang-han said, “ChongKunDang will leap into a global pharmaceutical company with a new CI and realize its future vision ‘Creative K-healthcare DNA(CKD)’ and we’ll achieve our commitment of contributing to making one person to all human to leading a healthy life through pharmaceutical technology innovation, from one person to all of humanity, from prevention to treatment.”
ChongKunDang Makes Equity Investment and R&D Partnership with AbClon
ChongKunDang struck a deal on an R&D partnership and strategic equity investment with the antibody new drug developer AbClon.
A signing ceremony took place at ChongKunDang headquarters in Chungjeong-ro, Seoul, on May 5, the Korean pharmaceutical company said.
Under the agreement, ChongKunDang will acquire 1.4 million registered common shares, or a 7.3 percent stake in AbClon, with the issuance of new shares.
ChongKunDang will receive priority rights to sell blood cancer chimeric antigen receptor T-cell (CAR-T) treatment “AT101 (Nespacel)” CAR-T, being developed by AbClon.
Both sides plan to build a comprehensive cooperate system for jointly developing and commercializing new CAR-T treatment and bispecific antibody-based new drugs.
AT101 is a new drug by AbClon that is conducting a Phase 2 clinical trial, with the goal of fast-track permission in 2025. If development is completed, ChongKunDang is expected to enter the CAR-T treatment market through domestic commercialization.
The two companies also plan to jointly develop HER2-targeted CAR-T treatment “AT501” as well as blood cancer, solid cancer, CAR-T treatments and bispecific antibody treatments targeting PSMA (prostate-specific membrane antigen), CD30 (protein) targeted therapies, and 4-1BB pathway modulators for T cell activation.
To this end, both sides have a strategy to cooperate on overall areas, ranging from the designating of development priorities to clinical testing, permission and commercialization, by establishing a joint development committee.
ChongKunDang President Kim Young-joo said, “The agreement calls for both companies’ establishing of a future-oriented partnership to develop global innovative new drugs by converging their core capabilities beyond simple investing, and we will secure global competitiveness to enter the global market by expanding our new drug portfolio based on AbClon’s next-generation immune cell therapy platform and its own antibody development technology.”
AbClon President Lee Jong-suh said, “The deal we struck with ChongKunDang with Korea’s top R&D knowhow is a full-fledged partnership growth model beyond the limitations of the Korean biotech, and AbClon will be reborn into an innovative platform treatment company rewriting global standards based on these.”
_종근당 84주년 창립 기념식.jpg)
